Innovative and Professional: Phio Pharmaceuticals Announces Registered Direct Offering Under Nasdaq Rules
Exciting News for Phio Pharmaceuticals Corp. New Investment Opportunities in the Biotechnology Sector Phio Pharmaceuticals Corp. Announces Stock Purchase and Sale Agreements Marlborough, Massachusetts–(Newsfile Corp. – December 23, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body’s immune cells…